DSCSA — Drug Supply Chain Security Act — Regulatory Reference

DSCSA requires interoperable, electronic, package-level tracing for prescription drugs across all trading partners — manufacturers, wholesalers, dispensers, and third-party logistics providers. When AI agents query trace data to investigate suspect or illegitimate products, or to automate supply chain decisions, that access must be governed with the same rigor as human access. Specifically, each agent must operate within an authorized trading partner boundary, and its data access must be logged in a way that supports downstream verification and investigation workflows. AutoPIL enforces this by registering trace data as a classified source and blocking access from agents whose registered role does not match an authorized trading partner designation.

DSCSA applies to any manufacturer, wholesale distributor, dispenser, or third-party logistics provider handling prescription drugs in the US. It applies to AI deployments the moment an agent accesses electronic product identifier data, serialization records, transaction history, or suspect-product investigation records. The FDA completed its stabilization period through late 2024 and into 2025, meaning full interoperable tracing requirements are now in active enforcement. Organizations using AI agents for supply chain analytics, shortage detection, or returns processing that touch DSCSA-covered data are in scope. Deployment model does not create an exemption — cloud-hosted agents are subject to the same trading partner boundaries as on-premises systems.

DSCSA's authorized trading partner (ATP) requirements restrict which entities can exchange transaction data, transaction history, and transaction statements. For AI agent deployments, this means agents must be scoped to the specific trading partner role they represent — a dispenser agent cannot query manufacturer-level serialization data unless that exchange is explicitly authorized. In practice, this requires agents to be registered with a declared role (manufacturer, wholesaler, dispenser) and bound to a policy that enforces the corresponding access boundary. AutoPIL's agent registry supports this directly: each agent entry carries its role and is bound to a policy (PHM-DSCSA-ATP-001) that enforces the authorized trading partner boundary before trace data is returned.

DSCSA requires trading partners to investigate suspect products, notify the FDA of illegitimate product findings, and quarantine affected inventory within defined timeframes. When AI agents are involved in flagging, routing, or escalating suspect-product events, the audit trail of which agent accessed which trace records — and under what policy — becomes material evidence in an FDA investigation. A generic application log is insufficient: investigators need tamper-evident records that tie each data access event to a specific agent identity, the policy version in effect at the time, and the decision outcome. AutoPIL's cryptographic audit chain provides exactly this — every agent access to trace data produces an immutable, chained record that cannot be retroactively altered.

FDA has authority to impose import alerts, refuse product entry, and pursue civil and criminal penalties for DSCSA violations. The primary enforcement risk for AI-enabled supply chains is that automated decisions — flagging products as suspect, releasing quarantined inventory, or bypassing a verification step — occur without an auditable record tying the decision to a human-accountable policy. If an AI agent accesses trace data outside its authorized trading partner role or takes action on unverified serialization data, the organization bears liability for the resulting product security failure. FDA's completed stabilization period means tolerance for interoperability gaps has ended. Companies should ensure every AI agent operating on DSCSA-covered data is registered, role-scoped, and producing auditable access records before any enforcement inquiry arrives.